conducted immunohistochemical testing on biopsy samples from breast cancer patients undergoing paclitaxel and cisplatin neoadjuvant chemotherapy to explore the potential of known ferroptosis-related genes ACSL4 and GPX4 as predictive markers for pathological complete response (140). This evidence concerns the gene GPX4 and breast cancer.